Several biomarkers on bone marrow–derived NK cells present in newly diagnosed patients before treatment have prognostic value to achievement of MRD negativity postconsolidation with a daratumumab-containing quadruplet regimen compared with standard of care. D-VTd, daratumumab plus bortezomib-thalidomide-dexamethasone; IFNγ, interferon-γ; ISS, international staging system; MM, multiple myeloma; MRD, minimal residual disease; NK, natural killer cell; TNF, tumor necrosis factor; VTd, Velcade-thalidomide-dexamethasone. Figure created with BioRender.com.